

Advisory Committee on Medicines

Meeting Statement

Meeting 50, Friday 4 April 2025

Section A: Premarket registration applications

At this meeting, the committee provided advice on 7 applications under evaluation by the TGA, as below.

Active ingredient (TRADENAME)	Sponsor	Therapeutic area	Application designations	
Applications for a 'new medicine' containing a new active substance (new chemical entity or new biological entity) not currently approved in Australia (Application Type A)				
donanemab (KISUNLA)	Eli Lilly Australia Pty Ltd	Alzheimer's Disease		
Nemolizumab (NEMLUVIO)	Galderma Australia Pty Ltd	Atopic Dermatitis, Prurigo Nodularis		
Omaveloxolone (SKYCLARYS)	Biogen Australia Pty Ltd	Friedrich's Ataxia	Orphan	
Gadopiclenol (ELUCIREM/VUEWAY)	Guerbet Australia Pty Ltd	Contrast Magnetic Resonance Imaging		
Pegunigalsidase alfa (ELFABRIO)	Chiesi Australia Pty Ltd	Fabry Disease		

PO Box 100 Woden ACT 2606 ABN 40 939 406 804 Phone: 1800 020 653 or 02 6289 4124 Fax: 02 6203 1605

Email: info@tga.gov.au https://www.tga.gov.au

Lonapegsomatropin (SKYTROFA)	Specialised Therapeutics Pharma Pty Ltd	Growth Hormone Deficiency			
Applications for a 'new indication', or additional therapeutic use, for an already approved medicine (Application Type C)					
IncobotulinumtoxinA (XEOMIN)	Merz Australia Pty Ltd	Limb Spasticity			

The dates of commencement of the evaluation of these applications are available at Prescription medicines: applications under evaluation, see: https://www.tga.gov.au/prescription-medicines-applications-under-evaluation

Further details of the ACM discussion and advice associated with these items may be released within the Australian Public Assessment Reports (AusPARs). To browse all AusPARs see: https://www.tga.gov.au/resources/auspar

Section B: Post-market items

The ACM was not asked to provide advice on a post-market or safety issue.

Further information

For further information on the Advisory Committee on Medicines, please visit:

https://www.tga.gov.au/about-tga/advisory-bodies-and-committees/advisory-committee-medicines-acm

or contact the ACM Secretary by email: ACM@health.gov.au.